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Abstract: This study examines the regional distribution of new life science company 
formation and highlights ‘hotspots’ of where new activity is relatively intense. The analysis 
indicates that there are generally two types of region, the first type contains life science 
clusters that were established during the early 2000s and the second type displayed little or 
no significant life science activity during this period. This study analyses survey data (n= 
580) and evidences new patterns of life science company activity within peripheral UK 
regions. The study shows that new life science activity is occurring away from the traditional 
‘Golden Triangle’ of London, Cambridge and Oxford. New life science company activity can 
be found in peripheral regions such as the East Midlands, Yorkshire and Humberside, the 
North West and in Scotland. 
The evidence contained in this study suggests that new UK life science company activity is 
supported by the presence of UK biotechnology incubators. During the early 2000s there 
were only a handful of biotechnology incubators in the UK, by 2012 there over twenty-five. 
This study provides evidence to suggest that UK biotechnology incubators play an important 
role in supporting new life science companies. Since the early 2000s, biotechnology 
incubators have appeared in the same regions that display significant levels of new life 
science company activity. Furthermore, significant proportions of new life science companies 
are located in biotechnology incubators within regions that displayed little or no significant 
life science activity during the early 2000s. This study demonstrates that biotechnology 
incubators have an important role to play in supporting regional innovation systems, 
especially within peripheral regions in the UK.  
 
1. Introduction  
 
Since the 1990s public policy makers and private 
investors have been creating biotechnology 
incubators with the aim of obtaining a foothold in 
what many presume is one of the hottest future 
industries.  Start-ups and early stage life science 
companies require access to specialist premises, 
services and technical support not traditionally  
 
 
 
 
available on science parks and business parks.  The 
life science industry comprises the medical 
technology sector and the biotechnology sector 
(BIS 2010). This study investigates recent patterns 
of new company growth within the UK life science 
industry and examines the regional distribution of 
new life science company formation whilst 
 
highlighting ‘hotspots’ of where new activity is 
relatively intense. This study investigates the 
twenty-five new UK biotechnology incubators that 
have appeared since 2001 and analyses the growth 
of new life science companies alongside the 
emergence of new biotechnology incubators at a 
regional and city level. The analysis provides 
observations that suggest biotechnology incubators 
in the UK play a significant role in supporting new 
life science company formation in traditional 
regions i.e. London and the South East, and more 
peripheral regions such as the East Midlands, 
Yorkshire & Humberside and the North West.  
2. New UK life science company activity 
& UK Biotechnology incubators during 
the early 2000s 
The UK has historically been strong within the 
worldwide pharmaceutical industry arena and many 
large pharmaceutical companies have based their 
research and development sites in the UK. A strong 
science base in the UK is evident when we look at 
the number of large pharmaceutical companies 
setting up operations in the UK. For example GSK 
in Stevenage and Ware, AstraZeneca at Alderley 
Park near Manchester and Loughborough, ROCHE 
in Hertfordshire, BASF in Nottingham, Merck, 
Sharp & Dohme Corporation (MSD) in Scotland to 
name a few. In 1998, six of the world’s top ten 
largest pharmaceutical companies had operations in 
the UK (Cooke 2001), although according to Swan 
et al (1998) despite the presence of these 
pharmaceutical heavyweights the UK was slow to 
develop a thriving biotechnology sector. 
2.1 Emergence of the UK biotechnology 
sector 
The emergence of the biotechnology sector as a 
new segment of the pharmaceutical industry, 
according to Pisano (2006) began with Genentech. 
This company was founded in 1976 and was the 
first commercial firm to fully exploit the potential 
of genetically engineered science. Subsequently 
biotechnology companies utilised their ability to 
embrace new technologies and successfully 
commercialise intellectual property and transfer 
knowledge from universities to the private sector. 
This enabled biotechnology firms, in some 
instances due to their smaller size and less 
bureaucratic environment to outperform large 
pharmaceutical research and development 
departments (Pisano 2006). The structure of a 
biotechnology firm is quite different to that of a 
vertically integrated pharmaceutical company that 
retains research and development in-house and 
relies heavily on finding the next ‘block-buster’ 
drug. 
2.2 Biotechnology company activity early 
2000s 
According to Shimasaki (2009) the science of 
biotechnology encompasses any application of 
engineering and technology applied to the life 
sciences and usually refers to the use of living 
organisms in the making of a product.  In 1996, 
using a narrow definition of the biotechnology 
sector, there were 221 specialist biotechnology 
companies in operation in the UK. Using a more 
broad definition i.e. including consultancy and 
services there were 460 firms employing as many 
as 40,000 people according to Lawton-Smith et al 
(1999). By 1999 the number of specialist UK 
biotechnology firms had increased to 270, 
according to Cooke (2001), the biotechnology 
industry firms were mainly located in clusters 
found in Cambridge (50 firms), Oxford (50 firms) 
and Surrey (37 firms) together with Scotland (over 
50 firms) and Wales (15 firms). This historical 
evidence suggests that in these traditional 
biotechnology regions during the late 1990s the UK 
possessed a strong pharmaceutical industry base 
and an emerging life science industry. 
There was relatively very little in the way of life 
science activity in peripheral regions such as the 
Midlands, Yorkshire & Humberside and the North 
West. Cities within these regions did not possess 
clusters of biotechnology company activity in the 
analysis of UK biotechnology clusters undertaken 
by Swan in 1998 and Cooke in 2001 (Swann et al 
1998 p-214). This earlier analysis of biotechnology 
clustering across the UK showed that Nottingham, 
Sheffield, Leeds and York possessed less than 3% 
of the total number of UK biotechnology 
companies, indicating that these areas did not 
display clusters of life science activity in the late 
1990s and early 2000s. According to Sainsbury 
(1999) these cities did not yet possess the company 
base (both start-ups and more mature biotechnology 
companies) which characterise clusters. 
2.3 Biotechnology incubators early 2000s 
During the late 1990s and early 2000s there were 
only a handful of biotechnology incubators 
designed to facilitate new biotechnology companies 
in operation throughout the UK (Sainsbury 1999 & 
Cooke 2001). Hence their presence did not appear 
to play a significant role in the growth of the life 
science industry or biotechnology sector in the UK 
during this period.  
In the late 1990s biotechnology incubators were 
based in Manchester, Babraham (Cambridge), 
Oxford, London, Cardiff and Edinburgh. 
Established UK biotechnology incubators were 
often geographically connected to research 
institutes or universities and since the late 1990s 
and early 2000s had played a limited role in 
contributing to the biotechnology sector. Few 
studies had been carried out on UK Biotechnology 
incubators. During the late 1990s and early 2000s 
biotechnology incubators were rarely mentioned in 
academic literature. 
The rare group of studies that include 
biotechnology incubators in the UK are centred on 
London and the South East of England. For 
example Lawton-Smith (2004) concentrates on 
Oxfordshire, Capser (2003) concentrates on the 
Cambridge. Reports detailing the biotechnology 
sector released by the Office of Business 
Innovation and Skills (BIS) and the Department of 
Trade and Industry (DTI) use case studies based on 
activity in the South East of England. However 
Cooke (2002) observed that Manchester 
Biosciences incubator established in the late 1990s 
had three goals.  The first was to manage all aspects 
of university-owned intellectual property relating to 
life sciences, including licensing deals, spinoffs, 
and joint ventures. The second was to manage the 
Manchester Incubator for young biotechnology 
companies and the third was to provide mentoring 
and incubation for university spinoffs.  
More recent studies suggest that biotechnology 
incubators do not make a significant contribute to 
supporting the emergence of new life science 
related companies. Oakey (2012) did not undertake 
an empirical study of biotechnology incubators 
however a review of the current literature by Oakey 
(2012) suggested that incubators play a limited role 
in supporting technological collaboration to 
improve research and development management 
within the high technology sector. One motivation 
of our study is to broaden the horizon and elucidate 
biotechnology incubation technology in the whole 
regional spectrum of the UK. 
3. Limitations of current research 
Our review of the literature on biotechnology 
incubation reveals several gaps of research. Firstly 
there is a lack of general studies on biotechnology 
incubation in the UK. The main interest of currently 
published academic research is on rather general 
characteristics of incubation types such as business 
incubator, technology incubators, university based 
incubators and incubators located on science parks. 
Biotechnology incubation is a rather recent 
phenomenon, therefore has not yet received 
attention from researchers. Thus, motivated by this 
gap in knowledge, this study will evidence the 
growth of new life science company activity and 
the emergence of new biotechnology incubators in 
the UK.  
4. Methodology 
We built two datasets to analyse patterns of new 
company growth within the UK life science 
industry. This allows us to analyse UK 
biotechnology incubators and their main 
characteristics. The desk based ‘UK life science 
start-up 2005-2012 survey’ provides a long term 
view on life science start-up companies across the 
UK and includes 580 UK life science companies 
established between 2005 and 2012. The survey 
examines the start-date of companies, their sector 
type, the region in which the company is based, the 
biotechnology incubator (if any) they are based in 
and the amount of external finance that has been 
secured by new life science start-up companies.  
4.1 UK life science company survey 
The ‘UK life science start-up 2005-2012’ survey 
provides contextual data to help understand some of 
the wider external influences that impact upon 
biotechnology incubation. For example regional 
trends and growth patterns of new biotechnology 
and medical technology start-up companies and 
regional comparisons of external venture capital 
investment secured by new life science companies. 
Data sweeps for new life science companies were 
carried out in 2010, 2011 and 2012 using the same 
methodology and systematic approach to data 
collection.  
 
 
 
Data sources  (‘UK life science start-up 2005-2011 survey’)  
Companies House DVD- Rom Directory 
Companies House Direct Web Check Service 
Technology Strategy Board 
Biotechnology incubator Websites 
Bio incubator tenant pipelines 
Universities Websites 
University technology transfer offices (total 38) 
UK Biotechgate Database 
UK Bioincubator Forum (UKBIF) 
FAME 
OBN News Feeds 
One Nucleus News Feeds 
UK Science Park Association (UKSPA) 
Investment Websites e.g. ‘Growth Business’ 
Venture Capital fund portfolios (total 25) 
Venture Market Index 
Development Agency Websites 
Science, technology & Business Park’s websites 
Bio Trinity showcase companies 
SpinoutsUK.co.uk database 
 
Table 1 – UK life science start-up survey Data sources 
Each data sweep consists of a 5 year period for 
example the 2010 sweep sought companies that 
starting trading between 1st January 2005 and 31st 
December 2010, the 2011 sweep found companies 
starting trading between 1st January 2006 and 31st 
December 2011 and so on. This provides a method 
to repeat the data collection exercise for missing 
companies that started trading in later years. 
Companies that started trading closer to the time of 
the sweep are harder to find, older companies have 
been active for longer and leave a more obvious 
trail.  
 
The main criteria that needed to be met for a 
company to be included in the dataset were that the 
company must be of an entrepreneurial nature, 
based in the UK and founded between the period of 
the data sweep i.e. 2005-2009, 2006-2010, 2007-
2011. The company must also be research or 
product focused, excluding consultants and 
advisers. The company must be sufﬁciently 
established. Non-operational entities that are 
companies in name only are excluded.  Subsidiaries 
of other companies are also excluded. Table 1 
provides an overview of the sources used to 
populate the dataset. 
4.2 UK biotechnology incubator survey 
The desk based ‘UK biotechnology incubator 
survey’ provides a detailed examination of the 
characteristics of 22 UK biotechnology incubators, 
the types of technical support on offer, physical 
details of the incubator such as size, and a 
breakdown of the incubator ‘tenant mix’ in terms of 
business model, company type and start-date.  The 
survey provides a snap-shot of the industry taken 
between December 2011 and January 2012 and 
contains data on 357 tenants companies. It is 
supplemented by 12 semi-structured interviews 
with CEO’s and Directors of UK biotechnology 
incubators. 
The survey concentrates on one aspect of the life 
science industry, UK biotechnology incubators and 
includes all UK biotechnology incubators in 
operation during January 2012, it is designed to 
provide information on individual tenant 
characteristics and attributes for every UK 
biotechnology incubator and their tenant 
companies. Tenant company characteristics 
provided by the UK biotechnology incubator 
survey include the start date of a company, sector 
type (i.e. biotechnology or medical technology) and 
business model utilised by each individual 
company. 
The ‘UK biotechnology incubator’ survey also 
examines the various types of supportive 
environments that biotechnology incubators 
provide. This includes provision of soft 
infrastructure and business support, technical 
support and equipment, financial support such as 
access to VC networks or investor readiness 
programmes.  
5. Patterns of new company growth 
within the UK life science industry  
To provide an overview of the life science start-up 
firms the ‘UK life science start-up 2005-2012’ 
assesses start-up activity in the life science sector 
between 2005 and 2011. The purpose of this survey 
is to provide contextual to place the classification 
of UK biotechnology incubators. Some 580 new 
biotechnology and medical technology companies 
have been established in the UK since 2005 
throughout the UK. Nearly two thirds (62.1%) are 
biotechnology start-ups and the remaining 37.9% 
are medical technology start-ups. Figure 1 shows 
that London and South East have the largest 
proportions of new life science start-up companies 
and there are significant numbers of new life 
science companies in peripheral regions such as the 
East Midlands and the North West. 
 
Figure 1 - Geographical distribution of new life science 
companies (sweep 1) 
5.1 New life science company growth in 
peripheral regions 
The number of life science start-ups is highest in 
the South East, East and London. This is to be 
expected due to the established biotechnology 
clusters operating in these regions (Sainsbury 1999, 
Cooke 2001), however these are not the only 
regions that display high levels of new life science 
activity.  
A major observation we can discern from figure 
1 is that the geographical distribution of new 
biotechnology company activity is not restricted to 
the traditional East and South East of England or 
the ‘Golden Triangle’. There are still significant 
levels of growth in these traditional biotechnology 
‘hot-spots’. After all, clusters of biotechnology 
activity have been present in these regions for over 
15 years (Cooke 2001, Swann et al, 1998).Another 
significant observation contained in figure 1 shows 
that there are relatively high levels of new life 
science company formation in peripheral regions of 
the UK such as the East Midlands and Yorkshire & 
Humberside (along the M1) and in the North West 
between Liverpool and Manchester (along the 
M56). 
5.2 Growth along the ‘M1 Corridor’ 
Figure 1 shows the development of new life science 
activity along the ‘M1 Corridor’ and clearly 
demonstrates the significant number of new life 
science companies in the Midlands and South 
Yorkshire & Humberside. Figure 1 shows that there 
is significant new life science activity in these 
localities, despite the lack of biotechnology clusters 
in these regions in the early 2000s. 
The East Midlands and Yorkshire & Humberside 
regions contain emerging biotechnology sectors and 
display a significant amount of new growth in life 
science company numbers from a low baseline. The 
major cities within the East Midlands and 
Yorkshire & Humberside, i.e. Nottingham, 
Sheffield and Leeds are home to Russell group 
universities with a strong science base.  These cities 
are also within relatively close proximity to one 
another. Nottingham, Sheffield and Leeds are 
within 70 miles of one another and connected by 
good transport links such as the M1 motorway and 
the Midland Mainline railway. Furthermore, it is a 
30 minute drive from Leeds to York where there is 
a biotechnology incubator based on York Science 
Park. Newly established and growing 
biotechnology clusters in the East Midlands and 
Yorkshire & Humberside form a corridor of activity 
along the M1 motorway. 
Combining the number life science companies in 
the East Midlands and Yorkshire & Humberside is 
plausible due to the relatively close geographical 
distribution of biotechnology companies within 
their major cities. The ‘M1 Corridor’ of activity 
contains a greater number of biotechnology 
companies than the North West, West Midlands, 
Wales or the North East. Figure 1 shows that the 
number of new life science companies that started 
trading between 2005 and 2012 located along the 
‘M1 corridor’ (122) is almost equal to the number 
of new life science companies in Scotland (130) 
and London (135). This finding may seem 
surprising but demonstrates that there is significant 
level of new life science company activity in 
localities other than the regions that had established 
biotechnology clusters in the late 1900s and early 
2000s.  
6. UK Biotechnology incubators 
Since 2001 a new generation of biotechnology 
incubators has appeared in UK cities. Along with 
the appearance of these biotechnology incubators, 
new concentrations of life science company activity 
developed. Table 2 shows that there are at least 19 
UK biotechnology incubators that have been 
established since 2001. There has been a five-fold 
increase in UK biotechnology companies from the 
later 1990s to the early 2010s evidenced in previous 
sections combined with the appearance of new life 
science activity in localities that did not display life 
science activity in the late 1990s may be to some 
extent, supported by the introduction of 
biotechnology incubators. 
6.1 Location of UK Biotechnology 
incubators 
UK biotechnology incubators are usually co-located 
with anchor institutions such as hospitals, 
universities, science parks or located in former 
pharmaceutical company research and development 
sites or. For example, The Imperial Incubator 
(London) and Queen Mary Bio (London) are on 
university sites, C-Tric (Northern Ireland) and 
Cardiff Medicentre (Wales) are co-located on 
Hospital sites and York Biocentre is co-located on 
York Science Park. BioCity Nottingham is based in 
the former BASF/Boots pharmaceutical research 
and development site; BioCity Scotland is located 
in the former pharmaceutical research and 
development site that once belonged to MERCK 
(Motherwell) and BioPark Hertfordshire is located 
at the site that was once owned by ROCHE 
(Welwyn). 
Table 2 - UK Biotechnology incubators  
 
 
  
Incubator Biotechnology Incubator description Region Start 
date 
London Bioscience 
Innovation Centre 
LBIC is owned and managed by the Royal Veterinary College (RVC). 
LBIC's clients range from entrepreneurial start-ups to more established 
UK businesses and overseas subsidiaries.    
London 2001 
BioCity 
Nottingham 
BioCity Nottingham is said to be one of Europe's largest bioscience 
incubators. Launched in 2003, the 129,000 sq. ft. award winning site 
currently hosts 70 companies and nearly 500 employees. A former BASF 
site. 
East 
Midlands 
2003 
Tetricus Bioscience 
incubator 
Tetricus Science Park based at Porton Down in Wiltshire, offers state-of-
the-art laboratory facilities and specialist support to new and growing 
science companies.  
South West 2003 
Mersey Bio 
Incubator 
Merseybio Incubator is a purpose built state-of-the-art facility for 
developing biotechnology businesses. owned by Liverpool University 
and run by 2Bio ltd. 
North West 2004 
BioPark 
Hertfordshire  
BioPark is managed by Exemplas on behalf of the University of 
Hertfordshire had been developed with funding from the East of England 
Development Agency. A former ROCHE research facility. 
South East 2006 
Cardiothoracic bio 
Incubator 
(Papworth) 
Provides an environment purpose built to pioneer new developments in 
diagnostic technology and medical treatments of disease promoting 
closer collaboration between academia, the N.HS and business  
East 2006 
Imperial Incubator The Imperial Incubator is a purpose built and provides office and 
laboratory space for early-stage companies offering access to Imperial 
College’s research base, technology transfer and funding networks 
London 2006 
Sheffield Bio 
Incubator 
The Sheffield Bioincubator is a purpose built facility providing the ideal 
environment for entrepreneurial bioscience to flourish into successful 
business with close proximity to existing tenants and the Sheffield 
universities. 
Yorks. & 
Humberside 
2006 
University of 
Bradford 
The Bioscience Business Incubator offers physical or virtual space to 
emerging companies The facilities are split between the Institutes of 
Cancer Therapeutics and Pharmaceutical Innovation. 
Yorks. & 
Humberside 
2006 
Queen Mary Bio 
science innovation 
centre 
The Queen Mary BioEnterprises Innovation Centre in London E1 is one 
of the largest purpose-built spaces in London for start-ups and more 
mature companies in science and technology. The 3 upper floors provide 
39,000 sq. ft. of laboratory space.  
London 2008 
Stevenage 
Bioscience Catalyst 
Provides “Access to world class resources and including superb high 
specification laboratories, funding and a vibrant community for 
biotechnology growth and development” based at GSK Site 
East 2012 
BioCity Scotland BioCity Scotland is a joint venture with Roslin Biocentre founded in 
2012. It has since become the centre for a wide range of research, 
training, events and thought leadership. A former MERCK facility.  
Scotland 2012 
BioHub Based on Astra Zenica Alderey Park research and development research 
site. 
North West 2013 
MediCity 
(Nottingham) 
Based on Boots (Beeston) Nottingham research and development site East 
Midlands 
2013 
C-TRIC This purpose built facilities primary objective is to reduce both the time 
to market and the costs associated with research and development of 
innovative health technologies, medical devices and therapeutics. 
Northern 
Ireland 
2009 
Institute of Life 
Sciences (ILS) 
(Swansea) 
The ILS is a  purpose-built medical research facility. It is a collaboration 
between Swansea University and the Welsh Government, Abertawe Bro 
Morgannwg University, Health Board, IBM and industry partners.  
Wales 2007 
DiagnOx DiagnOx was established to help improve the commercialisation of UK 
diagnostics research services tailored to meet the needs of the sector.  
South East 2001 
Norwich 
Bioincubator 
This incubator contains 12 laboratories providing support services that 
include biological, chemical and radiological waste management.. 
Tenants can test out a concept for a molecular biology based business. 
East 2002 
York Bio Centre The York Biocentre is a state of the art facility for biotechnology start-up 
and growth companies based in York Science Park.  
Yorks. & 
Humberside 
2009 
Newcastle Bio 
incubators 
Former Centre for Excellence in Life Science (CELS) operated 
biotechnology a bioincubator at the ‘Centre for life.. 
North East  
These various types of anchor institutions provide 
biotechnology incubators with access to different 
kinds of infrastructure support services and various 
types of life science knowledge. 
 
6.2 Size of UK biotechnology incubators
  
Biotechnology incubators can vary from a 
300sq. metre facility that can provide laboratory 
and write up space for between 6 and 8 tenant 
companies to facilities with up to 12,000 sq. metres 
with space for over 70 tenant companies. UK 
biotechnology incubators can be categorised on the 
basis of size i.e. small, medium and large. Small 
biotechnology incubators (300 to 2000sq. metres) 
include Cardiff Medicentre, DiagnOx, Leeds 
Bioincubator, LBIC, Mersey BIO and Papworth 
Cardiothoracic biotechnology incubator. A 
relatively high proportion of small incubators are 
university based and hospital based biotechnology 
incubators.     
Medium size incubators (2000 to 7000 sq. 
metres) can support between 10 and 23 tenant 
companies. They include BioPark Hertfordshire, 
Edinburgh Bioquarter, ILS Swansea, Queen Mary 
Bio, Roslin Bio in Edinburgh, UMIC, Sheffield Bio 
Incubator, Stevenage biocatalyst, Norwich Bio and 
York Bio. A significant proportion (45%) of UK 
biotechnology incubators can be categorised as 
medium sized. 
Large incubators (over 7000s q. metres) include 
Cambridge based Babraham incubator Babraham, 
BioCity Scotland and BioCity Nottingham.  
 
 
The two largest biotechnology incubators are 
BioCity Scotland and BioCity Nottingham and they 
are both stand-alone incubators of over 12,000 sq. 
metres in size. The two largest stand-alone 
biotechnology incubators are located in geographic 
areas that are not close to sources of life science 
knowledge i.e. universities or research institutes. 
These are not purpose built they are former large 
pharmaceutical drug research and development 
sites that have been regenerated to reuse existing 
laboratories. 
7. New UK life science companies 
operating from a UK biotechnology 
incubator 
Of the 580 new UK life science start-up companies 
(2005-2012) 39% have been based in a 
biotechnology incubator at some point in time. 
There have been fluctuations in the number of start-
ups based in biotechnology incubators over the 
years, 2005 saw only 20%. New start-up companies 
based in a biotechnology incubator increased quite 
sharply in 2006 to 56%. This increase corresponds 
with an increase in the size of the UK’s largest 
biotechnology incubator ‘BioCity Nottingham’ and 
the opening of medium size BioPark. The 
percentage of start-ups based in incubators then 
gradually decreased between 2007 and 2009 to 
23%, and has remained at this level up until 2011 
when the numbers started to increase again. 
  
Figure 2 – UK life science start-up data 
7.1 New life science company activity in 
traditional biotechnology regions 
The previous section of this study established that 
traditional biotechnology regions such as London, 
South East and Scotland are regions that possessed 
established biotechnology clusters in the late 1990s. 
These regions also have higher proportions of new 
life science companies that are not based in a 
biotechnology incubator. One explanation is that 
London, the South East and the East of England 
have had time to develop a sufficient infrastructure 
and sustainable clusters that have the ability to 
support the growth of new life science companies 
without the additional intervention from a 
biotechnology incubator. According to Sainsbury 
(1999) London and the South East already 
possessed the soft infrastructure that could support 
new life science companies in the late 1990s. 
 
Figure 2 uses data from the ‘UK life science 
start-up 2005-2012’ survey to indicate the 
proportion of new life science companies that 
operate from a UK biotechnology incubator. It is 
immediately apparent from figure 2 that there are 
pronounced regional variations in the percentage of 
new life science companies located in 
biotechnology incubators. London, Scotland, South 
East and Wales display high proportions of new life 
science companies that are not located within a 
biotechnology incubator.  
7.2 New life science company activity in 
peripheral regions 
The East Midlands, North West and Yorkshire & 
Humberside are regions with high proportions of 
new life science companies that are located within a 
biotechnology incubator. Figure 2 shows that 
regions with higher proportions of new life science 
companies located within a biotechnology 
incubator are much more likely to exist in 
peripheral regions i.e. outside of Oxford, 
Cambridge and London i.e. ‘beyond the golden 
triangle’ (Smith & Ehret 2012). A plausible 
explanation is that regions with new and emerging 
life science clusters are trying to ‘catch-up’ with 
established regions and biotechnology incubators 
are seen as way of achieving this. 
8. UK biotechnology incubators and new 
life science activity 
This study shows that since 2001 a new 
generation of biotechnology incubators has 
appeared in UK cities, along with the appearance of 
these biotechnology incubators, new concentrations 
of life science company activity developed. These 
second generation biotechnology incubators (see 
table 2) consist of both purpose built biotechnology 
incubators and biotechnology incubators that 
regenerate former large pharmaceutical drug 
research and development sites.  This study also 
shows that new life science activity has occurred in 
peripheral regions as well as tradition 
biotechnology regions. 
Table 3 highlights geographic locations that 
display significant proportions of activity of new 
life science companies. Table 3 also shows the total 
proportion of national life science activity 
(biotechnology sector and medical technology 
sector) for each UK region, this provides an 
indication of the level of new life science activity 
within that region. The table then shows the 
proportion of life science activity at a localised city 
level, this provides an indication of where life 
science activity appears within a region. Table 3 
also indicates whether or not a biotechnology 
incubator or Russell Group university is located 
near new life science activity This begins to 
illustrate the importance  of centres of scientific 
excellence and biotechnology incubator support in 
the development of life science cluster in the UK.  
8.1 Local concentrations of new life 
science activity  
Table 3 shows that concentrations of new life 
science activity are likely to be near a 
biotechnology incubator and this is evident for over 
75% of new UK life science activity. It seems that 
new regional life science activity is underpinned by 
geographic localities within regions that display 
high proportions of life science activity may be to 
some extent, supported by the introduction of 
biotechnology incubators.  
There are some localities within regions that 
display a high concentration of new life science 
companies and localities within the same region 
that display little or no activity. For example Table 
3 shows that in Scotland, new life science 
companies are widely dispersed thorough out the 
region, 59% of new life science companies are 
based in three localities Aberdeen, Glasgow and 
Edinburgh. In the East of England a high proportion 
of new life science companies are located in in 
Cambridge, near the Babraham institute. 
 
Table 3 –New UK life science activity a regional and local 
perspective (Sweep 1) 
 
Table 3 shows that in the North East, one city, 
Newcastle-Upon-Tyne represents 75% of new life 
science companies that started trading between 
2005 and 2009. In Wales 89% of new life science 
companies are based in Swansea or Cardiff. In the 
West Midlands 88% of new life science companies 
are based in Birmingham and Coventry.  It seems 
that there are concentrations of life science activity 
in particular localities within regions, and in many 
instances there is a biotechnology incubator present 
within these localities.  
8.2 New life science company local activity 
in peripheral regions 
The distribution of new life science companies in 
the East Midlands is quite revealing with a 
staggering 96% of new life science companies 
based in Nottingham. Table 3 shows that a very 
high proportion of new life science activity within 
this region is concentrated in one local area. 
Nottingham represents nearly all new life science 
activity in the East Midlands with Derby and 
Leicester playing an almost insignificant role in the 
location on new life science companies. In fact 81% 
of new life science companies in Nottingham are 
located within two miles of a Russell group 
university and located within a biotechnology 
incubator. This may not be a reflection of the 
ability of Derby and Leicester to create new life  
 
science companies themselves. It is plausible that 
new life science companies in the East Midlands 
simply choose to locate in Nottingham. 
This concentration of new life science 
companies in Nottingham is the start of the ‘M1 
Corridor’ of life science activity that occurs 
between Nottingham and Leeds. 96% of the East 
Midlands life science start-ups are based in 
Nottingham, 37 miles North along the M1 Sheffield 
possessed 38% of new life science companies and 
Leeds a further 35 miles North with 19% of new 
life science companies in Yorkshire & Humberside 
regions. When the distribution of new life science 
companies within the cities contained in the East 
Midlands and Yorkshire & Humberside are 
analysed in detail, it becomes apparent that there 
are significant numbers of new life science 
companies in cities along the ‘M1 corridor’ 
Furthermore is as apparent that a biotechnology 
incubator is present at each locality .  
To summarise there are variations in the number 
of new life science company formation across the 
UK at both a regional and city level. A key finding 
is that where there are relatively high levels of new 
life science activity, there is likely to be a 
biotechnology incubator present, especially in 
peripheral regions. An explanation for high 
concentrations of new life science companies in 
cities is the availability of resources that can 
support new life science activity. It seems that 
localised concentrations of new life science 
companies in cities are supported by the presence 
of a biotechnology incubator.  
Regional 
perspective 
Local perspective  
% of total national 
activity 
% of total regional 
activity 
Biotechnology Incubator Russell Group 
University 
Scotland  15 Aberdeen 15   
  Edinburgh 21 Roslin Bio  BioCity 
Scotland, Edinburgh Bio 
Quarter 
University of Edinburgh 
  Glasgow 23 BioCity Scotland University of Glasgow 
  Dundee 11   
Yorkshire & 
Humberside 
8 Leeds 19 Leeds Innovation centre University of Leeds 
  Sheffield 38 Sheffield Bioincubator Sheffield University 
  York 31 York Biocentre  
  Bradford 12 Bradford BioIncubator  
East 
Midlands  
7 Nottingham 96 BioCity Nottingham Nottingham University 
North East 4 Newcastle Upon Tyne 75 Newcastle biomedical/ 
Centre for Life 
University of Newcastle 
North West 10 Liverpool 29 Mersey Bio University of Liverpool 
  Manchester 35 UMIC University of Manchester 
  Bristol 40   
Wales 6 Swansea 56 ILS  
  Cardiff 33 Cardiff Medicentre Cardiff University 
West 
Midlands 
5 Birmingham 53 Birmingham research park Birmingham University 
  Coventry 35  University of Warwick 
9. Conclusions 
This study provides evidence to suggest that 
regions displaying relatively high proportions of 
new life science activity within their cities usually 
contain a biotechnology incubator within that same 
city. According to the ‘UK life science start-up 
2005-2012’ survey over 75% of the total national 
activity of new life science companies are located 
in a city with a biotechnology incubator. The East 
Midlands, West Midlands, Yorkshire & 
Humberside, North West and North East are UK 
regions that do not have a long established life 
science industry and did not have established 
biotechnology clusters in the late 1990s (Cooke 
2001). Hence, these regions do not have an 
established infrastructure that could support new 
life science companies.  
The findings in this study show that there is a 
continued growth of new life science companies in 
traditional biotechnology regions such as London 
and the East of England. Most noticeable  is the 
new growth of lice science companies in peripheral 
regions of the UK such as the East Midlands, 
Yorkshire & Humberside, West Midlands and to 
some extent the North West. In addition to this new 
life science company activity, there are a high 
proportion of new life science companies that are 
located within a biotechnology incubator. Within 
these peripheral regions biotechnology incubators 
seem to play a greater role in supporting new life 
science companies and may have been the catalyst 
to initiate new clusters of activity.  
Contained in this study is an example of an 
agglomeration displaying a relatively new 
concentration of life science activity with a high 
proportion of new life science companies located in 
several biotechnology incubators along ‘M1 
Corridor’ (From Nottingham J25 to Leeds J35). 
The findings show that high proportions (96%) of 
new life science companies in the East Midlands 
are concentrated in Nottingham and that a high 
proportion of new life science companies in the 
East Midlands are located within a biotechnology 
incubator. Similarly, there are local ‘hotspots’ of 
new life science company activity and high 
proportions new life science companies based 
within a biotechnology incubator in Sheffield, 
Leeds and York. 
The evidence suggests that in some cases regions 
with an established biotechnology cluster can still 
be reliant on biotechnology incubators to support 
new life science companies. The East of England is 
an example of such activity. A possible explanation 
is that traditional regions that are undergoing an 
expansion in the life science industry may 
potentially outgrow their native support 
infrastructure and require biotechnology incubators 
to provide additional support to facilitate new life 
science company growth. A major finding of this 
study suggests that biotechnology incubators may 
have an important role to play in developing 
concentrations of life science activity in localities 
where quite recently there was little new life 
science company activity. 
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